Comparative Safety and Benefit-Risk Profile of Biologics and
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to compare the short-term (12-16 weeks) and long-term (48-56 weeks) safety and benefit-risk profiles of moderate-to-severe psoriasis treatments that concluded Risankizumab had the most favorable benefit-risk profile in the long term.

A systematic literature review of Phase II-IV randomized controlled trials (RCTs) of moderate-to-severe psoriasis treatments was conducted. Any adverse events (AE), any serious AE (SAE), and AEs leading to treatment discontinuation were compared with Bayesian network meta-analyses (NMAs). 52 and 7 RCTs were included in the short- and long-term NMAs.

Results:
--In the short term, the rates of any AEs were lowest for tildrakizumab (posterior median: 46.0%), certolizumab (46.2%), and etanercept (49.1%).

--The rates of any SAE were lowest for certolizumab (0.8%), risankizumab (1.2%), and etanercept (1.6%).

--The rates of AEs leading to treatment discontinuation were lowest for risankizumab (0.5%), tildrakizumab (1.0%), and guselkumab (1.5%).

--In the long term, risankizumab had the lowest rates of all three outcomes (67.5%, 4.4% and 1.0%, respectively) and the most favorable benefit-risk profile.

In particular, Anti-IL-23 agents were associated with low rates of safety events. Risankizumab had the most favorable benefit-risk profile in the long term.

Source: https://www.jaad.org/article/S0190-9622(21)00422-9/fulltext?rss=yes
1 share
Like
Comment
Share